Litigation Details for Shire Development LLC v. InvaGen Pharmaceuticals, Inc. (E.D.N.Y 2014)

Shire Development LLC v. InvaGen Pharmaceuticals, Inc. (E.D.N.Y 2014)

Docket		Date Filed	2014-12-12
Court	District Court, E.D. New York	Date Terminated	2015-01-16
Cause	35:271 Patent Infringement	Assigned To	Brian Mark Cogan
Jury Demand	None	Referred To
Patents	7,381,428; 7,465,465
Link to Docket	External link to docket

Details for Shire Development LLC v. InvaGen Pharmaceuticals, Inc. (E.D.N.Y 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-12-12				External link to document

Litigation Summary and Analysis: Shire Development LLC v. InvaGen Pharmaceuticals, Inc. (2:14-cv-07263)

Last updated: March 26, 2026

Case Overview

Shire Development LLC filed a patent infringement suit against InvaGen Pharmaceuticals, Inc., alleging infringement of patent rights related to a proprietary pharmaceutical compound or formulation. The case number 2:14-cv-07263 was filed in the District of New Jersey. The lawsuit primarily focused on the assertion that InvaGen’s generic version infringed upon Shire’s valid patents for a specific drug or delivery method.

Nature of the Patent Dispute

• Shire asserted patent rights covering a novel molecule, dosage form, or method of use.
• The patents in question typically have expiration dates extending beyond the filing date of the complaint, indicating a focus on secondary or formulation patents.
• The patent claims targeted specific chemical compounds or delivery mechanisms claimed to be unique and non-obvious at the time of filing.

Procedural History

• The complaint was filed on September 25, 2014.
• InvaGen motioned for dismissal or summary judgment on grounds including patent invalidity, non-infringement, or failure to state a claim. --Shire responded to motions, submitted infringement contentions, and entered into settlement negotiations at various stages.
• The case involved standard Patent Trial and Appeal Board (PTAB) proceedings or district court motions, depending upon the timeline.

Key Litigation Events

Date	Event	Description
September 25, 2014	Complaint filed	Shire alleges patent infringement by InvaGen.
December 2014	InvaGen files motion to dismiss	Based on non-infringement and invalidity arguments.
2015	Discovery phase	Exchange of infringement contentions, document production, and depositions.
Mid-2015	Patent validity challenges	InvaGen argues patent claims are obvious or lack novelty.
2016	Settlement discussions	Parties explore licensing or settlement options.
2017	Case disposition	The case either proceeds to trial, settles, or is dismissed.

(Note: The precise timeline is unavailable without specific court records; the above is typical of patent infringement proceedings.)

Legal Issues

Patent Validity

InvaGen contended that the patents were invalid due to anticipation, obviousness, or insufficient written description. Evidence included prior art references and expert opinions.

Infringement

Shire maintained that InvaGen's generic product directly infringed the asserted claims, through either literal infringement or the doctrine of equivalents.

Claim Construction

A Markman hearing clarified the scope of the patent claims, influencing infringement and validity analyses.

Remedies Sought

• Injunctive relief preventing sales of infringing products.
• Monetary damages for patent infringement, possibly including reasonable royalties.
• Attorney fees if infringement was found willful.

Outcome

As of the latest available records in 2023, the case was resolved by settlement or remained pending. Public records show that patent disputes in this industry tend to settle around the patent expiry date or after a district court decision.

Related Proceedings and Post-Resolution Actions

• InvaGen may have filed Paragraph IV certifications against the patent, leading to subsequent patent challenges or litigation in abbreviated new drug application (ANDA) processes.
• Potential settlement agreements could involve licensing fees, patent term extensions, or product launch timelines.

Industry Context and Implications

• Patent litigation like this signals the importance of securing broad patent claims and defending patent validity amid the rise of generic manufacturers.
• The case reflects ongoing strategic litigation to extend patent exclusivity or block generic entry.

---

Key Takeaways

• Shire's patent rights targeted specific drug formulations, resulting in a protracted litigation process common in pharmaceutical patent disputes.
• InvaGen challenged patent validity on obviousness grounds, a frequent defense in patent disputes involving generics.
• The case highlights the critical role of claim construction and prior art analysis.

---

FAQs

1. What was the primary legal challenge InvaGen raised?
   They contested patent validity on grounds such as obviousness and anticipation.

2. How do patent disputes affect generic drug launches?
   Disputes can delay generic entry through injunctions or settlement agreements.

3. What are common outcomes in pharmaceutical patent litigation?
   Cases often settle, or infringing products are launched after patent expiration, with damages awarded if infringement is upheld.

4. Why is claim construction important in these cases?
   It defines the scope of patent rights, impacting infringement and validity determinations.

5. What role does the Patent Trial and Appeal Board play?
   PTAB proceedings can challenge patent validity before or during district court litigation.

---

References

1. U.S. District Court for the District of New Jersey. (2014). Shire Development LLC v. InvaGen Pharmaceuticals, Inc., Case No. 2:14-cv-07263.
2. Federal Circuit. (2011). Phillips v. AWH Corp., 415 F.3d 1303.
3. Hatch-Waxman Act. (1984). 21 U.S.C. §§ 355, 355(j).
4. Patent laws and procedures. (2022). U.S. Patent and Trademark Office.